Pages that link to "Q44219909"

The following pages link to Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer (Q44219909):

Displaying 37 items.

• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors (Q26828860) (← links)
• EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer (Q27851583) (← links)
• Chromosomal and genomic changes in lung cancer (Q33781119) (← links)
• Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands (Q34129430) (← links)
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular (Q34159011) (← links)
• ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice (Q34974942) (← links)
• Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy (Q35623628) (← links)
• Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer (Q35898597) (← links)
• Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis (Q36040002) (← links)
• EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort (Q36048238) (← links)
• Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries (Q36179200) (← links)
• Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis (Q36352476) (← links)
• High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR. (Q36793862) (← links)
• Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives (Q37004639) (← links)
• The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer (Q37194315) (← links)
• Emerging options for the management of non-small cell lung cancer (Q37269316) (← links)
• Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California (Q37393760) (← links)
• Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis (Q37476827) (← links)
• Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. (Q37579644) (← links)
• Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment (Q37754925) (← links)
• Pathogen comparative genomics in the next-generation sequencing era: genome alignments, pangenomics and metagenomics. (Q37971380) (← links)
• EGFR gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis (Q38963470) (← links)
• A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas (Q39975984) (← links)
• Treatments and outcomes of advanced/recurrent non-small cell lung cancer harboring the EGFR T790M mutation: a retrospective observational study of 141 patients in Japan (Q40570622) (← links)
• Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation (Q42582783) (← links)
• The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs (Q42949613) (← links)
• Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations (Q43272211) (← links)
• Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients (Q44070495) (← links)
• Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer (Q44485092) (← links)
• Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma (Q45272652) (← links)
• Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. (Q46255351) (← links)
• Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas (Q51607504) (← links)
• Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. (Q54653324) (← links)
• Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma (Q80731960) (← links)
• [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer] (Q84643820) (← links)
• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer (Q84911213) (← links)
• Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study (Q89928323) (← links)